期刊
BIOTECHNOLOGY AND BIOENGINEERING
卷 119, 期 1, 页码 48-58出版社
WILEY
DOI: 10.1002/bit.27945
关键词
adenovirus; distributed manufacturing; vaccine
资金
- AstraZeneca
- UK Department for Business, Energy and Industrial Strategy
- Engineering and Physical Sciences Research Council [EP/R013756/1]
- UK Research and Innovation [MC_PC_19058]
- EPSRC [EP/R013756/1] Funding Source: UKRI
In response to the COVID-19 pandemic, we have developed an effective vaccine based on novel manufacturing technologies, allowing for large-scale production and distributed manufacturing to ensure international supply security and cost-effectiveness.
Manufacturing has been the key factor limiting rollout of vaccination during the COVID-19 pandemic, requiring rapid development and large-scale implementation of novel manufacturing technologies. ChAdOx1 nCoV-19 (AZD1222, Vaxzevria) is an efficacious vaccine against SARS-CoV-2, based upon an adenovirus vector. We describe the development of a process for the production of this vaccine and others based upon the same platform, including novel features to facilitate very large-scale production. We discuss the process economics and the distributed manufacturing approach we have taken to provide the vaccine at globally-relevant scale and with international security of supply. Together, these approaches have enabled the largest viral vector manufacturing campaign to date, providing a substantial proportion of global COVID-19 vaccine supply at low cost.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据